NextBioMedical Co

NextBioMedical Co Debt / Assets

The Debt-to-Assets Ratio of NextBioMedical Co (389650.KQ) as of Nov 20, 2026 is 0.02. In the previous year, Debt-to-Assets Ratio was 0.11 — a change of -85.21% (lower).

Debt / Assets

0.02

YoY

-85.21%

Last updated:

Debt-to-Assets Ratio of NextBioMedical Co is 2025 0.02 . Debt-to-Assets Ratio of NextBioMedical Co was 2024 0.11 . It decreases by -85.21% lower compared to the previous year.

The NextBioMedical Co Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2022
0.19 KRW
Jan 1, 2023
0.22 KRW
Jan 1, 2024
0.11 KRW
Jan 1, 2025
0.02 KRW
The NextBioMedical Co Debt / Assets history
YEARDebt / AssetsYoY
0.02-85.21%
0.11-51.13%
0.22+15.40%
0.19—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NextBioMedical Co Stock analysis

What does NextBioMedical Co do? NextBioMedical Co Ltd generates revenue through the manufacturing and sales of medical equipment, including endoscopic hemostatic agents and vascular embolic microspheres. The company focuses on research and development within the health care equipment and supplies sector, targeting healthcare providers and medical institutions that require specialized equipment for procedures such as endoscopy and vascular interventions. Its products are designed to address specific clinical needs, supporting both diagnostic and therapeutic applications in medical settings. The company operates in the Health Care Equipment & Supplies industry, with a primary focus on Korea-based manufacturing and sales. Its product portfolio includes endoscopic hemostatic agents, which are used to control bleeding during endoscopic procedures, and vascular embolic microspheres, utilized in embolization treatments for vascular conditions. These products are sold to hospitals and medical facilities that require advanced medical solutions for patient care. NextBioMedical Co Ltd's business model relies on the consistent demand for specialized medical equipment in the healthcare sector. By developing and commercializing products such as endoscopic hemostatic agents and vascular embolic microspheres, the company serves healthcare providers seeking reliable and innovative tools for minimally invasive procedures. The company's research and development efforts aim to enhance product efficacy and expand its market presence within the medical equipment industry. NextBioMedical Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NextBioMedical Co stock

Debt-to-Assets Ratio of NextBioMedical Co is 0.02 in 2025.

Debt-to-Assets Ratio of NextBioMedical Co changed from 0.11 to 0.02, representing a -85.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio NextBioMedical Co since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's NextBioMedical Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — NextBioMedical Co

All Key Metrics — NextBioMedical Co